Naproxen
Colo-rectal Cancer
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Colo-rectal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Modufolin Isofol Medical AB | Phase 3 | BB |
Pentoxifylline Tanta University | Phase 2 | BB |
Dkn-01 Leap Therapeutics, Inc. | Phase 2 | B |
Montanide Isa 51 Roswell Park Cancer Institute | Phase 1/2 | CCC |
vv1 Vyriad, Inc. | Phase 2 | CCC |
View all 28 →
Same molecule, other indications
Naproxen is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →